pegaspargase
Selected indexed studies
- Pegaspargase. (, 2006) [PMID:32697465]
- Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit. (Curr Hematol Malig Rep, 2021) [PMID:33978914]
- Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. (J Clin Oncol, 2021) [PMID:34228505]
_Worker-drafted node — pending editorial review._
Connections
pegaspargase is a side effect of
Sources
- Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. (2021) pubmed
- Pegaspargase. (2006) pubmed
- Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit. (2021) pubmed
- Pegaspargase: A Review in Acute Lymphoblastic Leukaemia. (2019) pubmed
- Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia. (2020) pubmed
- Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. (2023) pubmed
- Pegaspargase: an alternative? (1997) pubmed
- First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial. (2024) pubmed
- Recognition, prevention, and management of adverse events associated with asparaginase/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel. (2025) pubmed
- Pegaspargase-induced hypertriglyceridemia. (2018) pubmed